Castle Biosciences Announces Commercial Launch of DecisionDx-SCC
Prognostic gene expression profile test for metastatic risk in cutaneous squamous cell carcinoma now available to clinicians in the
Conference Call and webcast today at
“We are pleased to offer DecisionDx-SCC, intended for use in adding actionable, patient-specific information to risk assessment and to help guide management decisions in SCC,” said
The DecisionDx-SCC test is a qRT-PCR assay of 40 genes that uses a neural network algorithm to classify patients into risk categories. Independent validation was performed in a prospectively designed, multi-center (33 sites) study using archival tissue from 420 patients with known 3-year outcomes. The test’s validity and impact are supported by four peer-reviewed publications.
Conference Call and Webcast Details
As previously announced,
A live webcast of the conference call can be accessed here: https://edge.media-server.com/mmc/p/ffayujyd or via the webcast link on the Investor Relations page of the Company’s website (www.castlebiosciences.com). Slides to be presented during the webcast will also be available on the Investor Relations page of the Company’s website. Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company’s website until
To access the live conference call via phone, please dial (877) 282-2581 from
There will be a brief Question & Answer session following prepared remarks.
About Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (SCC) is one of the most common cancers. Approximately 1 million patients are diagnosed with SCC each year in the
About DecisionDx-SCC
DecisionDx-SCC is a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors. The test result, in which patients are stratified into a Class 1, 2A or 2B risk category, predicts individual metastatic risk to inform risk-appropriate management.
Peer-reviewed publications have demonstrated that DecisionDx-SCC is an independent predictor of metastatic risk and that integrating DecisionDx-SCC with current prognostic methods can add positive predictive value to clinician decisions regarding staging and management.
More information about the test and disease can be found at www.mySCCskincancer.com.
About
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq and are trademarks of
Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning the benefits and contributions offered by DecisionDx-SCC, including for risk assessment and patient treatment; usefulness of the information provided by DecisionDx-SCC analysis; and physician adoption of DecisionDx-SCC and related plans for commercialization. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on our business and our efforts to address its impact on our business and our ability to maintain compliance with the covenants in our debt facility, the timing and amount of revenue we are able to recognize in a given fiscal period, unexpected delays in planned launch of our pipeline products, the level and availability of reimbursement for our products, our ability to manage our anticipated growth and the risks set forth in our Annual Report on Form 10-K for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005174/en/
Investor Contact:
832-835-5158
czuckero@castlebiosciences.com
Media Contact:
315-879-8192
ajobe@lifescicomms.com
Source: